EU/3/09/702: Orphan designation for the treatment of malaria

Beta-artemether / lumefantrine

Table of contents


On 28 January 2010, orphan designation (EU/3/09/702) was granted by the European Commission to Dafra Pharma International NV, Belgium, for beta-artemether / lumefantrine (powder for oral suspension) for the treatment of malaria.

Key facts

Active substance
  • Beta-artemether
  • lumefantrine
Intended use
Treatment of malaria
Orphan designation status
EU designation number
Date of designation
Dafra Pharma International NV
Slachthuisstraat 30/7
2300 Turnhout
Telephone: +32 14 61 78 20
Telefax: +32 14 61 78 59

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating